Uncategorized

ORPHELIA Pharma awarded a grant from the region Île-de-France to support business activity development in Europe and in the US

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

ORPHELIA Pharma and Ethypharm sign a licensing agreement for the development and marketing of Kigabeq® in China

Six new projects supported by our Foundation and our Endowment Fund

During the Board of Directors in December 2020, we supported 6 new projects: concerts at the hospital with the CIMCL, a saddle adapted for donkey rides with Handiane, computer equipment and furniture for AKA.MA, school for deaf children and the centers for disabled people Les Roseaux, Orchidées Blanches and Anyma.

Amolyt Pharma Announces Research Collaboration with PeptiDream

Newsletter December 2020

This newsletter outlines the last projects we have supported during the second half of 2020

Three new projects supported by our Foundation

The 22nd of october 2020, the board of directors of the Foundation Dominique & Tom Alberici decided to support the Moebius Syndrome Association France, Au-delà de nos handicaps and the Saint-Vincent medicalized foster home

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog AZP-3601

ORPHELIA Pharma to organize a Symposium at the SIOP 2020 congress on Friday October 16th

ORPHELIA announces the inclusion of the first patient in a clinical study evaluating Kimozo, its pediatric formulation of temozolomide